Skip to main content
Top
Published in: Osteoporosis International 12/2013

01-12-2013 | Review

Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group

Authors: M. Hiligsmann, M. Salas, D. A. Hughes, E. Manias, F. H. Gwadry-Sridhar, P. Linck, W. Cowell

Published in: Osteoporosis International | Issue 12/2013

Login to get access

Abstract

This study aims to systematically review, critically appraise and identify from the published literature, the most effective interventions to improve medication adherence in osteoporosis. A literature search using Medline, EMBASE, Cochrane library, and Cumulative Index to Nursing and Allied Health Literature was undertaken to identify prospective studies published between January 1, 1999 and June 30, 2012. We included studies on adult users of osteoporosis medications that tested a patient adherence intervention (e.g., patient education, intensified patient care, different dosing regimens) and reported quantitative results of adherence. The Delphi list was modified to assess the quality of studies. Of 113 articles identified, 20 studies fulfilled the inclusion criteria. The most frequent intervention was education (n = 11) followed by monitoring/supervision (n = 4), drug regimens (n = 2), drug regimens and patient support (n = 1), pharmacist intervention (n = 1), and electronic prescription (n = 1). Although patient education improved medication adherence in four studies, two large-scale randomized studies reported no benefits. Simplification of dosing regimens (with and without patient support program) was found to have a significant clinical impact on medication adherence and persistence. Monitoring/supervision showed no impact on medication persistence while electronic prescription and pharmacist intervention increased medication adherence or persistence. In conclusion, this review found that simplification of dosing regimens, decision aids, electronic prescription, or patient education may help to improve adherence or persistence to osteoporosis medications. We identified wide variation of quality of studies in the osteoporosis area. The efficacy of patient education was variable across studies, while monitoring/supervision does not seem an effective way to enhance medication adherence or persistence.
Appendix
Available only for authorised users
Literature
1.
go back to reference Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef
2.
go back to reference Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951PubMedCrossRef Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951PubMedCrossRef
3.
go back to reference Rabenda V, Hiligsmann M, Reginster J-Y (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303–2315PubMedCrossRef Rabenda V, Hiligsmann M, Reginster J-Y (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303–2315PubMedCrossRef
4.
go back to reference Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818PubMedCrossRef Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818PubMedCrossRef
5.
go back to reference Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRef Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRef
6.
go back to reference Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RMC, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13PubMedCrossRef Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RMC, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13PubMedCrossRef
7.
go back to reference Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170–177PubMedCrossRef Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170–177PubMedCrossRef
8.
go back to reference Landfeldt E, Lundkvist J, Strom O (2011) The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48:380–388PubMedCrossRef Landfeldt E, Lundkvist J, Strom O (2011) The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48:380–388PubMedCrossRef
9.
go back to reference Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15:604–612PubMedCrossRef Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15:604–612PubMedCrossRef
10.
go back to reference Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394–401PubMedCrossRef Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394–401PubMedCrossRef
11.
go back to reference Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202–210CrossRef Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202–210CrossRef
12.
go back to reference McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288:2868–2879PubMedCrossRef McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288:2868–2879PubMedCrossRef
13.
go back to reference Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev CD000011 Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev CD000011
14.
go back to reference Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–1271PubMedCrossRef Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–1271PubMedCrossRef
15.
go back to reference Gleeson T, Iversen MD, Avorn J et al (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127–2134PubMedCrossRef Gleeson T, Iversen MD, Avorn J et al (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127–2134PubMedCrossRef
16.
go back to reference Verhagen AP, de Vet HC, de Bie RA et al (1998) The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51:1235–1241PubMedCrossRef Verhagen AP, de Vet HC, de Bie RA et al (1998) The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51:1235–1241PubMedCrossRef
17.
go back to reference Blalock SJ, DeVellis BM, Patterson CC, Campbell MK, Orenstein DR, Dooley MA (2002) Effects of an osteoporosis prevention program incorporating tailored educational materials. Am J Health Promot 16:146–156PubMedCrossRef Blalock SJ, DeVellis BM, Patterson CC, Campbell MK, Orenstein DR, Dooley MA (2002) Effects of an osteoporosis prevention program incorporating tailored educational materials. Am J Health Promot 16:146–156PubMedCrossRef
18.
go back to reference Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef
19.
go back to reference Cook PF, Emiliozzi S, McCabe MM (2007) Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 22:445–456PubMedCrossRef Cook PF, Emiliozzi S, McCabe MM (2007) Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 22:445–456PubMedCrossRef
20.
go back to reference Delmas PD, Vrijens B, Eastell R et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRef Delmas PD, Vrijens B, Eastell R et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRef
21.
go back to reference Nielsen D, Ryg J, Nielsen W, Knold B, Nissen N, Brixen K (2010) Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ Couns 81:155–160PubMedCrossRef Nielsen D, Ryg J, Nielsen W, Knold B, Nissen N, Brixen K (2010) Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ Couns 81:155–160PubMedCrossRef
22.
go back to reference Ojeda-Bruno S, Naranjo A, Francisco-Hernandez F et al (2011) Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates. Osteoporos Int 22:1821–1828PubMedCrossRef Ojeda-Bruno S, Naranjo A, Francisco-Hernandez F et al (2011) Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates. Osteoporos Int 22:1821–1828PubMedCrossRef
23.
go back to reference Robbins B, Rausch KJ, Garcia RI, Prestwood KM (2004) Multicultural medication adherence: a comparative study. J Gerontol Nurs 30:25–32PubMed Robbins B, Rausch KJ, Garcia RI, Prestwood KM (2004) Multicultural medication adherence: a comparative study. J Gerontol Nurs 30:25–32PubMed
24.
go back to reference Shu AD, Stedman MR, Polinski JM et al (2009) Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care 15:417–424PubMed Shu AD, Stedman MR, Polinski JM et al (2009) Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care 15:417–424PubMed
25.
go back to reference Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905PubMedCrossRef Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905PubMedCrossRef
26.
go back to reference Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317–326PubMedCrossRef Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317–326PubMedCrossRef
27.
go back to reference Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X (2006) Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 17:664–671PubMedCrossRef Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X (2006) Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 17:664–671PubMedCrossRef
28.
go back to reference Heilmann RM, Friesleben CR, Billups SJ (2012) Impact of a pharmacist-directed intervention in postmenopausal women after fracture. Am J Health Syst Pharm 69:504–509PubMedCrossRef Heilmann RM, Friesleben CR, Billups SJ (2012) Impact of a pharmacist-directed intervention in postmenopausal women after fracture. Am J Health Syst Pharm 69:504–509PubMedCrossRef
29.
go back to reference Hill DA, Cacciatore M, Lamvu GM (2010) Electronic prescribing influence on calcium supplementation: a randomized controlled trial. Am J Obstet Gynecol 202(236):e1–e5 Hill DA, Cacciatore M, Lamvu GM (2010) Electronic prescribing influence on calcium supplementation: a randomized controlled trial. Am J Obstet Gynecol 202(236):e1–e5
30.
go back to reference Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725–1735PubMedCrossRef Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725–1735PubMedCrossRef
31.
go back to reference Lai PS, Chua SS, Chew YY, Chan SP (2011) Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. J Clin Pharm Ther 36:557–567PubMedCrossRef Lai PS, Chua SS, Chew YY, Chan SP (2011) Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. J Clin Pharm Ther 36:557–567PubMedCrossRef
32.
go back to reference Montori VM, Shah ND, Pencille LJ et al (2011) Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 124:549–556PubMedCrossRef Montori VM, Shah ND, Pencille LJ et al (2011) Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 124:549–556PubMedCrossRef
33.
go back to reference Roux C, Giraudeau B, Rouanet S, Dubourg G, Perrodeau E, Ravaud P (2011) Monitoring of bone turnover markers does not improve persistence with ibandronate treatment. Joint Bone Spine 79:389–392PubMedCrossRef Roux C, Giraudeau B, Rouanet S, Dubourg G, Perrodeau E, Ravaud P (2011) Monitoring of bone turnover markers does not improve persistence with ibandronate treatment. Joint Bone Spine 79:389–392PubMedCrossRef
34.
go back to reference Silverman SL, Nasser K, Nattrass S, Drinkwater B (2012) Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial. Osteoporos Int 23:1069–1074PubMedCrossRef Silverman SL, Nasser K, Nattrass S, Drinkwater B (2012) Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial. Osteoporos Int 23:1069–1074PubMedCrossRef
35.
go back to reference Solomon DH, Iversen MD, Avorn J et al (2012) Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med 172:477–483PubMedCrossRef Solomon DH, Iversen MD, Avorn J et al (2012) Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med 172:477–483PubMedCrossRef
36.
go back to reference Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT (2010) Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int 21:391–398PubMedCrossRef Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT (2010) Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int 21:391–398PubMedCrossRef
37.
go back to reference Gwadry-Sridhar FH, Manias E, Zhang Y et al (2009) A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther 31:421–435PubMedCrossRef Gwadry-Sridhar FH, Manias E, Zhang Y et al (2009) A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther 31:421–435PubMedCrossRef
38.
go back to reference Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10:3–12PubMedCrossRef Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10:3–12PubMedCrossRef
39.
go back to reference Vrijens B, De Geest S, Hughes DA et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691–705PubMedCrossRef Vrijens B, De Geest S, Hughes DA et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691–705PubMedCrossRef
Metadata
Title
Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group
Authors
M. Hiligsmann
M. Salas
D. A. Hughes
E. Manias
F. H. Gwadry-Sridhar
P. Linck
W. Cowell
Publication date
01-12-2013
Publisher
Springer London
Published in
Osteoporosis International / Issue 12/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2364-z

Other articles of this Issue 12/2013

Osteoporosis International 12/2013 Go to the issue